DEXCOM, INC. Professional Fees
DEXCOM, INC. (DXCM) reported Professional Fees of $40.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-07-30
- DEXCOM, INC. professional fees for the quarter ending 2026-06-30 was $40.80M, a 16.24% increase year-over-year.
- DEXCOM, INC. professional fees for the quarter ending 2026-03-31 was $35.20M, a 7.65% increase year-over-year.
- DEXCOM, INC. professional fees for the quarter ending 2025-12-31 was $38.10M, a 27.70% decline year-over-year.
- DEXCOM, INC. professional fees for the quarter ending 2025-09-30 was $33.10M, a 44.74% decline year-over-year.
- DEXCOM, INC. professional fees for fiscal 2025 was $139.00M, a 38.98% decline from fiscal 2024.
- DEXCOM, INC. professional fees for fiscal 2024 was $227.80M, a 2.52% increase from fiscal 2023.
- DEXCOM, INC. professional fees for fiscal 2023 was $222.20M, a 13.14% increase from fiscal 2022.
- DEXCOM, INC. professional fees for fiscal 2022 was $196.40M.
| Period end | Professional Fees 3 month | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.80M 10-Q · filed 2026-07-30 | $76.00M 10-Q · filed 2026-07-30 | $114.10M derived: sum of 3 quarters · filed 2026-07-30 | $147.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $35.20M 10-Q · filed 2026-04-30 | $73.30M derived: sum of 2 quarters · filed 2026-04-30 | $106.40M derived: sum of 3 quarters · filed 2026-04-30 | $141.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $38.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $71.20M derived: sum of 2 quarters · filed 2026-02-12 | $106.30M derived: sum of 3 quarters · filed 2026-07-30 | $139.00M 10-K · filed 2026-02-12 |
| 2025-09-30 | $33.10M 10-Q · filed 2025-10-30 | $68.20M derived: sum of 2 quarters · filed 2026-07-30 | $100.90M 10-Q · filed 2025-10-30 | $153.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $35.10M 10-Q · filed 2026-07-30 | $67.80M 10-Q · filed 2026-07-30 | $120.50M derived: sum of 3 quarters · filed 2026-07-30 | $180.40M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $32.70M 10-Q · filed 2026-04-30 | $85.40M derived: sum of 2 quarters · filed 2026-04-30 | $145.30M derived: sum of 3 quarters · filed 2026-04-30 | $202.50M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $52.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $112.60M derived: sum of 2 quarters · filed 2026-02-12 | $169.80M derived: sum of 3 quarters · filed 2026-02-12 | $227.80M 10-K · filed 2026-02-12 |
| 2024-09-30 | $59.90M 10-Q · filed 2025-10-30 | $117.10M derived: sum of 2 quarters · filed 2025-10-30 | $175.10M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $57.20M 10-Q · filed 2025-07-30 | $115.20M 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $58.00M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $222.20M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $196.40M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |